Arrowhead Pharmaceuticals (NASDAQ:ARWR) shares rise 23% after Plozasiran Phase 3 data released
Arrowhead Pharmaceuticals’ (ARWR) shares rose 23.4% to $91.96 after it released Phase 3 Plozasiran (SHASTA-3/4) data. The company reported 79%-81% median triglyceride reductions and 78% fewer pancreatitis events versus placebo, with all prespecified endpoints met. Arrowhead said it will file a supplemental submission by year-end; complete datasets are due Aug. 30.
How this was made
The 30-second read
Why it matters
The immediate market impact is a large, catalyst-driven repricing of ARWR based on prespecified endpoint achievement and quantified efficacy, with remaining uncertainty around complete datasets and regulatory verification.
Market read
A same-day, company-specific Phase 3 topline catalyst with quantified efficacy and no new safety concerns is driving a major ARWR move, with the next decision point at Aug 30 for comprehensive results and a year-end supplemental filing.
What to watch
Plozasiran’s four injections per year versus higher-frequency comparators is a commercial lever, but the article flags that complete datasets are not yet released and regulators have not verified the broader assertion.
Background
The article frames Arrowhead’s Plozasiran Phase 3 SHASTA-3 and SHASTA-4 topline results, contrasting efficacy versus placebo and noting upcoming comprehensive results at ESC Congress.
Ticker impact
Arrowhead shares jumped 23.4% after SHASTA-3 and SHASTA-4 hit prespecified endpoints for Plozasiran, including 79% to 81% triglyceride reductions.
Near-term volatility likely remains elevated into the Aug 30 ESC Congress release of comprehensive results and any supplemental U.S. filing.
The article cites prespecified endpoint achievement, quantifies efficacy (triglycerides and pancreatitis events), and notes no new safety concerns, which are direct catalysts for ARWR’s valuation.
Market effects
Strength in a biotech lipid/pancreatitis pipeline can lift sentiment for triglyceride and pancreatitis therapeutics, though XBI was down on the day.
Primarily U.S. biotech tape impact given NASDAQ listing and U.S. FDA label context for the comparator.
ESC Congress timing suggests broader European scientific scrutiny and potential international investor attention around safety and subgroup efficacy.
Counterpoint
Topline is not the full dataset; cross-trial comparisons and unverified broader claims could lead to post-conference giveback if subgroup efficacy or safety details disappoint.
Key entities
- companyArrowhead Pharmaceuticals
ARWR surged after SHASTA-3 and SHASTA-4 prespecified endpoints were achieved for Plozasiran, with large triglyceride and pancreatitis reductions reported.
- drugPlozasiran
Investigational therapy in SHASTA-3/4; reported to lower median triglycerides 79% to 81% at 12 months and reduce pancreatitis events by 78%.
- clinical_trialsSHASTA-3 and SHASTA-4
Phase 3 studies whose prespecified endpoints were reported as achieved, with no new safety concerns mentioned.
- companyIonis Pharmaceuticals
Comparator context: Ionis’ Tryngolza label broadened June 24 and U.S. availability begins in July; Ionis stock was mostly unchanged in the article.
- etfSPDR S&P Biotech ETF (XBI)
Biotech benchmark referenced as down 1.0% while ARWR rose sharply, highlighting idiosyncratic strength.
